www.fdanews.com/articles/196752-bis-ofev-approved-in-europe-for-interstitial-lung-disease
BI’s OFEV Approved in Europe for Interstitial Lung Disease
April 22, 2020
The European Commission has approved Boehringer Ingelheim’s Ofev (nintedanib) for treatment of systemic sclerosis-associated interstitial lung disease.
The approval was based on results from a phase 3 clinical trial which showed that Ofev slowed the loss of pulmonary function in patients with the disease.
The FDA approved Ofev for systemic sclerosis-associated interstitial lung disease in September 2019.